专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090160977A1 SYSTEM FOR MULTI-MEDIA IMAGE MAGNIFICATION 审中-公开
标题翻译：多媒体图像放大系统
公开(公告)号：US20090160977A1
公开(公告)日：2009-06-25
申请号：US12272327
申请日：2008-11-17
申请人： Timothy M. Curtin , Michael J. Roberts
发明人： Timothy M. Curtin , Michael J. Roberts
IPC分类号： H04N5/262
CPC分类号： H04N7/18
摘要： A vision magnification system includes a fixed work area, a camera, and drive mechanism capable of moving the camera in at least one direction. The vision magnification system provides a magnified image of an object for viewing by a user and is particularly useful for individuals having impaired vision. A control device includes a pointing device, to control movement of the camera in a direction provided by the user, and a tracking device, which can be coupled to a writing instrument to control movement of the camera when the user uses the writing instrument.
摘要翻译：视觉放大系统包括固定的工作区域，照相机和能够至少沿一个方向移动照相机的驱动机构。视觉放大系统提供用户观看的物体的放大图像，并且对于视力受损的个体特别有用。控制装置包括指示装置，用于控制摄像机在由用户提供的方向上的移动;以及跟踪装置，跟踪装置可以耦合到书写工具，以在用户使用书写工具时控制相机的移动。

2. 发明授权

US08530653B2 Enzyme inhibiting compounds 失效
标题翻译：酶抑制化合物
公开(公告)号：US08530653B2
公开(公告)日：2013-09-10
申请号：US12939556
申请日：2010-11-04
申请人： Michael J. Roberts
发明人： Michael J. Roberts
IPC分类号： C07D239/72 , C07D487/00 , A01N43/54 , A01N43/90
CPC分类号： C07D239/95 , A61K31/517
摘要： The present invention is directed to compounds that are specifically structured to provide enzyme inhibition. In specific embodiments, the enzyme inhibiting compounds exhibit antifolate activity. Particularly, the inventive compounds are formed of an antifolate residue that is active in inhibiting one or more of TS, DHFR, GAR, FPGS, and AICAR Tfase. The enzyme inhibiting compounds are useful in a variety of methods of treatment, including treating abnormal cell proliferation and treating inflammation.
摘要翻译：本发明涉及特异性结构化以提供酶抑制的化合物。在具体实施方案中，酶抑制化合物表现出抗叶酸活性。特别地，本发明化合物由有效抑制TS，DHFR，GAR，FPGS和AICAR Tfase中的一种或多种的抗叶酸残基形成。酶抑制化合物可用于各种治疗方法，包括治疗异常细胞增殖和治疗炎症。

3. 发明申请

US20130035528A1 REMOVAL OF HYDROGEN SULFIDE AS AMMONIUM SULFATE FROM HYDROPYROLYSIS PRODUCT VAPORS 有权
公开(公告)号：US20130035528A1
公开(公告)日：2013-02-07
申请号：US13196645
申请日：2011-08-02
申请人： Terry L. Marker , Larry G. Felix , Martin B. Linck , Michael J. Roberts
发明人： Terry L. Marker , Larry G. Felix , Martin B. Linck , Michael J. Roberts
IPC分类号： C10G1/00 , C07C7/14
CPC分类号： C10G1/002 , B01D53/52 , B01D53/75 , B01D2255/705 , B01D2257/304 , C01B3/38 , C01B2203/0233 , C01C1/022 , C01C1/026 , C01C1/247 , C05C3/00 , C10G1/06 , C10G3/50 , C10G2300/1011 , C10G2300/207 , C10G2400/02 , C10G2400/04 , C10G2400/08 , C10J2300/0966 , C10K1/004 , C10L1/04 , C10L2200/0469 , Y02E50/32 , Y02E50/343 , Y02P20/145 , Y02P20/52 , Y02P30/20 , Y02W30/47
摘要： A system and method for processing biomass into hydrocarbon fuels that includes processing a biomass in a hydropyrolysis reactor resulting in hydrocarbon fuels and a process vapor stream and cooling the process vapor stream to a condensation temperature resulting in an aqueous stream. The aqueous stream is sent to a catalytic reactor where it is oxidized to obtain a product stream containing ammonia and ammonium sulfate. A resulting cooled product vapor stream includes non-condensable process vapors comprising H2, CH4, CO, CO2, ammonia and hydrogen sulfide.

4. 发明授权

US08329876B2 Thioester-terminated water soluble polymers and method of modifying the N-terminus of a polypeptide therewith 有权
标题翻译：硫酯封端的水溶性聚合物和用其修饰多肽的N末端的方法
公开(公告)号：US08329876B2
公开(公告)日：2012-12-11
申请号：US13282129
申请日：2011-10-26
申请人： Michael J. Roberts , Zhihao Fang
发明人： Michael J. Roberts , Zhihao Fang
IPC分类号： C07K17/02 , C08G63/50
CPC分类号： C07K1/13 , A61K47/60
摘要： The invention provides reagents and methods for conjugating a polymer specifically to the α-amine of a polypeptide. The invention provides monofunctional, bifunctional, and multifunctional PEGs and related polymers having a terminal thioester moiety capable of specifically conjugating to the α-amine of a polypeptide having a cysteine or histidine residue at the N-terminus. The invention provides reactive thioester-terminated PEG polymers that have suitable reactivity with an N-terminal cysteine or histidine residue of a polypeptide to produce an amide bond between the PEG molecule and the polypeptide.
摘要翻译：本发明提供了将聚合物与多肽的α-胺特异性缀合的试剂和方法。本发明提供了具有能够在N末端具有半胱氨酸或组氨酸残基的多肽的α-胺特异性缀合的末端硫酯部分的单功能，双官能和多官能PEG和相关聚合物。本发明提供了具有与多肽的N-末端半胱氨酸或组氨酸残基的合适反应性的反应性硫酯封端的PEG聚合物，以在PEG分子和多肽之间产生酰胺键。

5. 发明授权

US08165119B2 System and method of enabling a transparent Ethernet switch 有权
标题翻译：启用透明以太网交换机的系统和方法
公开(公告)号：US08165119B2
公开(公告)日：2012-04-24
申请号：US12164266
申请日：2008-06-30
申请人： Hendrich M. Hernandez , Robert L. Winter , Bruce A. Holmes , Michael J. Roberts
发明人： Hendrich M. Hernandez , Robert L. Winter , Bruce A. Holmes , Michael J. Roberts
IPC分类号： H04L12/56
CPC分类号： G06F13/387 , H04L49/351
摘要： A system and method of enabling a transparent Ethernet switch are disclosed. According to an aspect, a network switch is disclosed. The network switch can include a plurality of physical ports configured to communicate data via a network. The network switch can further include a memory configured to store a first forwarding database, and a plurality of aggregate zone entries within the first forwarding database. The aggregate zone entries can also include a port identifier of first port of the plurality of physical ports to be used as a transparent port within a first aggregate zone.
摘要翻译：公开了一种启用透明以太网交换机的系统和方法。根据一方面，公开了一种网络交换机。网络交换机可以包括经配置以经由网络传送数据的多个物理端口。网络交换机还可以包括被配置为存储第一转发数据库的存储器和第一转发数据库内的多个聚合区域条目。聚合区域条目还可以包括要用作第一聚合区域内的透明端口的多个物理端口的第一端口的端口标识符。

6. 发明授权

US07951812B2 Substituted pyrrolo[2,3-d]pyrimidines as antifolates 有权
标题翻译：取代的吡咯并[2,3-d]嘧啶作为抗叶酸剂
公开(公告)号：US07951812B2
公开(公告)日：2011-05-31
申请号：US12016528
申请日：2008-01-18
申请人： Michael J. Roberts , Simon Pedder
发明人： Michael J. Roberts , Simon Pedder
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00 , A61P29/00 , A61P11/06 , A61P19/02
CPC分类号： C07D487/04
摘要： The present invention is directed to antifolate compounds having the structure wherein: X is CHR9 or NR9; Y1, Y2, and Y3 independently are O or S; V1 and V2 independently are O, S, or NZ; Z is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or alkaryl; R1 and R2 independently are H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or alkaryl; R3 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, hydroxyl, or halo; and R4, R5, R6, R7, R8, and R9 independently are H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, acyl, —C(O)-alkyl, —C(O)-alkenyl, or —C(O)—alkynyl; as well as pharmaceutically acceptable esters, amides, salts, solvates, and prodrugs thereof. The compounds are useful in pharmaceutical compositions and in methods of treating multiple conditions, including abnormal cell proliferation, inflammatory diseases, asthma, and arthritis.
摘要翻译：本发明涉及具有以下结构的抗叶酸化合物：其中：X为CHR 9或NR 9; Y1，Y2和Y3独立地为O或S; V1和V2独立为O，S或NZ; Z是H，任选取代的烷基，任选取代的烯基，任选取代的炔基或烷芳基; R 1和R 2独立地为H，任选取代的烷基，任选取代的烯基，任选取代的炔基或烷芳基; R 3是H，任选取代的烷基，任选取代的烯基，任选取代的炔基，任选取代的烷氧基，羟基或卤素; R 4，R 5，R 6，R 7，R 8和R 9分别是H，任选取代的烷基，任选取代的烯基，任选取代的炔基，酰基，-C（O） - 烷基，-C（O） - 烯基或-C （O） - 炔基; 以及其药学上可接受的酯，酰胺，盐，溶剂合物和前药。该化合物可用于药物组合物和治疗多种病症的方法，包括异常细胞增殖，炎性疾病，哮喘和关节炎。

7. 发明授权

US07829708B2 Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation 有权
标题翻译：用于治疗异常细胞增殖和炎症疾病的代谢惰性抗叶酸剂
公开(公告)号：US07829708B2
公开(公告)日：2010-11-09
申请号：US11223433
申请日：2005-09-08
申请人： Michael J. Roberts , Simon Pedder
发明人： Michael J. Roberts , Simon Pedder
IPC分类号： C07D239/72 , A61K31/519
CPC分类号： C07D239/95
摘要： The present invention provides compositions and methods for the treatment of disorders of abnormal cell proliferation and/or inflammation, such as psoriasis and inflammatory bowel disease, in a human or other host animals.
摘要翻译：本发明提供了用于治疗人或其他宿主动物中异常细胞增殖和/或炎症疾病如牛皮癣和炎症性肠病的组合物和方法。

8. 发明授权

US07511095B2 Thioester-terminated water soluble polymers and method of modifying the N-terminus of a polypeptide therewith 有权
标题翻译：硫酯封端的水溶性聚合物和用其修饰多肽的N末端的方法
公开(公告)号：US07511095B2
公开(公告)日：2009-03-31
申请号：US11353656
申请日：2006-02-13
申请人： Michael J. Roberts , Zhihao Fang
发明人： Michael J. Roberts , Zhihao Fang
IPC分类号： C08G63/50
CPC分类号： C07K1/13 , A61K47/60
摘要： The invention provides reagents and methods for conjugating a polymer specifically to the α-amine of a polypeptide. The invention provides monofunctional, bifunctional, and multifunctional PEGs and related polymers having a terminal thioester moiety capable of specifically conjugating to the α-amine of a polypeptide having a cytokine or histidine residue at the N-terminus. The invention provides reactive thioester-terminated PEG polymers that have suitable reactivity with an N-terminal cysteine or histidine residue of a polypeptide to produce an amide bond between the PEG molecule and the polypeptide.
摘要翻译：本发明提供用于将聚合物与多肽的α-胺特异性缀合的试剂和方法。本发明提供了具有能够在N末端具有细胞因子或组氨酸残基的多肽的α-胺特异性缀合的末端硫酯部分的单功能，双官能和多功能的PEG和相关聚合物。本发明提供了具有与多肽的N-末端半胱氨酸或组氨酸残基的合适反应性的反应性硫酯封端的PEG聚合物，以在PEG分子和多肽之间产生酰胺键。

9. 发明申请

US20090023705A1 DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF MOOD DISORDERS, SLEEP DISORDERS OR ATTENTION DEFICIT DISORDERS 有权
标题翻译：治疗恶臭症，睡眠障碍或注意缺陷性疾病的杀虫剂及其药物组合物
公开(公告)号：US20090023705A1
公开(公告)日：2009-01-22
申请号：US12116560
申请日：2008-05-07
申请人： Michael J. Roberts , Simon Pedder
发明人： Michael J. Roberts , Simon Pedder
IPC分类号： A61K31/553 , A61K31/195 , A61K31/275 , A61K31/12 , A61K31/445 , A61P25/20 , A61P25/24 , A61P25/22 , A61K31/135 , A61K31/44 , A61K31/5375 , A61K31/137
CPC分类号： A61K31/198 , A61K31/135 , A61K31/137 , A61K31/138 , A61K31/195 , A61K31/275 , A61K31/277 , A61K31/345 , A61K31/55 , A61K45/06 , A61K2300/00
摘要： The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a compound selected from the group consisting of DOPA decarboxylase inhibiting compounds, catechol-O-methyltransferase inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiting compounds, selective serotonin reuptake inhibiting compounds, tricyclic antidepressant compounds, serotonin norepinephrine reuptake inhibiting compounds, norepinephrine dopamine reuptake inhibiting compound, noradrenergic and specific serotonergic antidepressants, and combinations thereof. The inventive compositions are particularly useful in the treatment of depression, narcolepsy, insomnia, and Attention Deficit/Hyperactivity Disorder (AD/HD).
摘要翻译：本发明提供药物组合物，其包含单独的droxidopa或与一种或多种其它活性成分组合用于治疗诸如情绪障碍，睡眠障碍或注意力缺陷障碍的病症的药物组合物。在某些实施方案中，可用于本发明方法的组合物包含droxidopa和选自DOPA脱羧酶抑制化合物，儿茶酚-O-甲基转移酶抑制化合物，胆碱酯酶抑制化合物，单胺氧化酶抑制化合物，去甲肾上腺素再摄取抑制化合物，选择性5-羟色胺再摄取抑制化合物，三环抗抑郁化合物，5-羟色胺去甲肾上腺素再摄取抑制化合物，去甲肾上腺素多巴胺再摄取抑制化合物，去甲肾上腺素能和特异性5-羟色胺能抗抑郁药，及其组合。本发明的组合物特别可用于治疗抑郁症，发作性睡病，失眠和注意力缺陷/多动障碍（AD / HD）。

10. 发明申请

US20080221170A1 DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF FIBROMYALGIA 有权
标题翻译：用于治疗纤维瘤的抗氧化剂及其药物组合物
公开(公告)号：US20080221170A1
公开(公告)日：2008-09-11
申请号：US12044680
申请日：2008-03-07
申请人： Michael J. Roberts , Simon Pedder
发明人： Michael J. Roberts , Simon Pedder
IPC分类号： A61K31/4412 , A61K31/198 , A61K31/44 , A61P19/04 , A61K31/165
CPC分类号： A61K31/195 , A61K31/198 , A61K31/277 , A61K31/435 , A61K2300/00
摘要： The present invention provides methods of treating fibromyalgia or other diseases or conditions causing widespread pain and/or fatigue. In particular, the invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active agents, that can be used in the inventive methods. The methods of treatment can comprise treating, preventing, reducing, or eliminating a variety of symptoms recognized as indicative of fibromyalgia, such as chronic pain, allodynia, hyperalgesia, fatigue, sleep disturbance, and depression.
摘要翻译：本发明提供治疗纤维肌痛或引起广泛的疼痛和/或疲劳的其它疾病或病症的方法。特别地，本发明提供药物组合物，其包含单独使用地洛西多或与一种或多种可用于本发明方法的其它活性剂组合。治疗方法可以包括治疗，预防，减少或消除被认为是指示纤维肌痛的各种症状，例如慢性疼痛，异常性疼痛，痛觉过敏，疲劳，睡眠障碍和抑郁症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式